The role of the MRTF-A/SRF pathway in ocular fibrosis

Investigative Ophthalmology and Visual Science

Volumn 55, Issue 7, 2014, Pages 4560-4567

  Yu Wai Man, Cynthia ^a,b   Treisman, Richard ^b   Bailly, Maryse ^a   Khaw, Peng Tee ^a  

^a UNIVERSITY COLLEGE LONDON   (United Kingdom)

^b IMPERIAL CANCER RESEARCH FUND   (United Kingdom)

Author keywords

MRTF A; Ocular fibrosis; Scarring; SRF; Transcription factors

Indexed keywords

BEVACIZUMAB; COLLAGENASE 3; CONNECTIVE TISSUE GROWTH FACTOR; DAUNORUBICIN; DICLOFENAC; EPIDERMAL GROWTH FACTOR; FLUOROURACIL; GELATINASE A; GELATINASE B; GUANINE NUCLEOTIDE EXCHANGE FACTOR; ILOMASTAT; INTERLEUKIN 1; INTERLEUKIN 6; INTERSTITIAL COLLAGENASE; MATRIX METALLOPROTEINASE 14; MITOGEN ACTIVATED PROTEIN KINASE P38; MITOMYCIN; MYOCARDIN RELATED TRANSCRIPTION FACTOR A; MYOCARDIN RELATED TRANSCRIPTION FACTOR B; RANIBIZUMAB; SCATTER FACTOR; SERUM RESPONSE FACTOR; STRESS ACTIVATED PROTEIN KINASE; STROMELYSIN; TRANSCRIPTION FACTOR; TRANSCRIPTION FACTOR AP 1; TRANSFORMING GROWTH FACTOR BETA; TUMOR NECROSIS FACTOR ALPHA; UNCLASSIFIED DRUG; UNINDEXED DRUG; VASCULOTROPIN;

ANGIOGENESIS; ANTERIOR EYE SEGMENT; ARTICLE; CAPSULE OPACIFICATION; CATARACT; CONJUNCTIVA; CORNEA; CORNEA NEOVASCULARIZATION; EYE INFECTION; EYE INFLAMMATION; GENE EXPRESSION; GLAUCOMA; HUMAN; INTRAOCULAR PRESSURE; MULTICENTER STUDY (TOPIC); NONHUMAN; OCULAR FIBROSIS; PATHOGENESIS; POSTERIOR EYE SEGMENT; PRIORITY JOURNAL; PROTEIN EXPRESSION; RANDOMIZED CONTROLLED TRIAL (TOPIC); SCAR FORMATION; SIGNAL TRANSDUCTION; TRABECULAR MESHWORK;

MRTF-A; OCULAR FIBROSIS; SCARRING; SRF; TRANSCRIPTION FACTORS;

DNA-BINDING PROTEINS; EYE; FIBROSIS; HUMANS; MATRIX METALLOPROTEINASES; ONCOGENE PROTEINS, FUSION; SERUM RESPONSE FACTOR;

EID: 84904790970     PISSN: 01460404     EISSN: 15525783     Source Type: Journal    
DOI: 10.1167/iovs.14-14692     Document Type: Article

References (121)

1. Miralles F, Posern G, Zaromytidou AI, Treisman R. Actin dynamics control SRF activity by regulation of its coactivator MAL. Cell. 2003;113:329-342.
2. Vartiainen MK, Guettler S, Larijani B, Treisman R. Nuclear actin regulates dynamic subcellular localization and activity of the SRF cofactor MAL. Science. 2007;316:1749-1752.
3. Posern G, Treisman R. Actin' together: serum response factor, its cofactors and the link to signal transduction. Trends Cell Biol. 2006;16:588-596.
4. Olson EN, Nordheim A. Linking actin dynamics and gene transcription to drive cellular motile functions. Nat Rev Mol Cell Biol. 2010;11:353-365.
5. Small EM, Thatcher JE, Sutherland LB, et al. Myocardin-related transcription factor-a controls myofibroblast activation and fibrosis in response to myocardial infarction. Circ Res. 2010; 107:294-304.
6. Luchsinger LL, Patenaude CA, Smith BD, Layne MD. Myocardin-related transcription factor-A complexes activate type I collagen expression in lung fibroblasts. J Biol Chem. 2011;286:44116-44125.
7. Crider BJ, Risinger GM Jr, Haaksma CJ, Howard EW, Tomasek JJ. Myocardin-related transcription factors A and B are key regulators of TGF-b1-induced fibroblast to myofibroblast differentiation. J Invest Dermatol. 2011;131:2378-2385.
8. Minami T, Kuwahara K, Nakagawa Y, et al. Reciprocal expression of MRTF-A and myocardin is crucial for pathological vascular remodelling in mice. EMBO J. 2012;31:4428-4440.
9. Fini ME. Keratocyte and fibroblast phenotypes in the repairing cornea. Prog Retin Eye Res. 1999;18:529-551.
10. Fautsch MP, Johnson DH. Aqueous humor outflow: what do we know? Where will it lead us?Invest Ophthalmol Vis Sci. 2006;47:4181-4187.
11. Addicks EM, Quigley HA, Green WR, Robin AL. Histologic characteristics of filtering blebs in glaucomatous eyes. Arch Ophthalmol. 1983;101:795-798.
12. Wong TTL, Sethi C, Daniels JT, Limb GA, Murphy G, Khaw PT. Matrix metalloproteinases in disease and repair processes in the anterior segment. Surv Ophthalmol. 2002;47:239-256.
13. Wong TTL, Mead AL, Khaw PT. Matrix metalloproteinase inhibition modulates postoperative scarring after experimental glaucoma filtration surgery. Invest Ophthalmol Vis Sci. 2003;44:1097-1103.
14. Daniels JT, Cambrey AD, Occleston NL, et al. Matrix metalloproteinase inhibition modulates fibroblast-mediated matrix contraction and collagen production in vitro. Invest Ophthalmol Vis Sci. 2003;44:1104-1110.
15. Westermarck J, Kahari VM. Regulation of matrix metalloproteinase expression in tumor invasion. FASEB J. 1999;13: 781-792.
16. Ishiguro N, Ito T, Miyazaki K, Iwata H. Matrix metalloproteinases, tissue inhibitors of metalloproteinases, and glycosaminoglycans in synovial fluid from patients with rheumatoid arthritis. J Rheumatol. 1999;26:34-40.
17. Prescott MF, Sawyer WK, Von Linden-Reed J, et al. Effect of matrix metalloproteinase inhibition on progression of atherosclerosis and aneurysm in LDL receptor-deficient mice overexpressing MMP-3, MMP-12, and MMP-13 and on restenosis in rats after balloon injury. Ann N Y Acad Sci. 1999;878:179-190.
18. Ye HQ, Azar DT. Expression of gelatinases A and B, and TIMPs 1 and 2 during corneal wound healing. Invest Ophthalmol Vis Sci. 1998;39:913-921.
19. Ye HQ, Maeda M, Yu F, Azar DT. Differential expression of MT1-MMP (MMP-14) and collagenase III (MMP-13) genes in normal and wounded rat corneas. Invest Ophthalmol Vis Sci. 2000;41:2894-2899.
20. Kvanta A, Sarman S, Fagerholm P. Expression of matrix metalloproteinase-2 (MMP-2) and vascular endothelial growth factor (VEGF) in inflammation-associated corneal neovascularization. Exp Eye Res. 2000;70:419-428.
21. Azar DT, Hahn TW, Jain S, Yeh YC, Stetler-Stevensen WG. Matrix metalloproteinases are expressed during wound healing after excimer laser keratectomy. Cornea. 1996;15: 18-24.
22. Alexander JP, Samples JR, Van Duskirk EM, Acott TS. Expression of matrix metalloproteinases and inhibitor by human trabecular meshwork. Invest Ophthalmol Vis Sci. 1991;32:172-180.
23. Bradley J, Vranka J, Colvis CM, et al. Effect of matrix metalloproteinases activity on outflow in perfused human organ culture. Invest Ophthalmol Vis Sci. 1998;39:2649-2658.
24. McCluskey P, Molteno A, Wakefield D, Di Girolamo N. Otago Glaucoma Surgery Outcome Study: the pattern of expression of MMPs and TIMPs in bleb capsules surrounding molteno implants. Invest Ophthalmol Vis Sci. 2009;50:2161-2164.
25. Esnault C, Stewart A, Gualdrini F, et al. Rho-actin signaling to the MRTF coactivators dominates the immediate transcriptional response to serum in fibroblasts. Genes Dev. 2014;28: 943-958.
26. Howard EW, Crider BJ, Updike DL, et al. MMP-2 expression by fibroblasts is suppressed by the myofibroblast phenotype. Exp Cell Res. 2012;318:1542-1553.
27. Kim KR, Bae JS, Choi HN, et al. The role of serum response factor in hepatocellular carcinoma: an association with matrix metalloproteinase. Oncol Rep. 2011;26:1567-1572.
28. Zhe X, Yang Y, Schuger L. Imbalanced plasminogen system in lymphangioleiomyomatosis, potential role of serum response factor. Am J Respir Cell Mol Biol. 2005;32:28-34.
29. Yan C, Boyd D. Regulation of matrix metalloproteinase gene expression. J Cell Physiol. 2007;211:19-26.
30. Chakraborti S, Malay Mandal M, Das S, Mandal A, Chakraborti T. Regulation of matrix metalloproteinases: an overview. Mol Cell Biochem. 2003;253:269-285.
31. Sotozono C, Inatomi T, Nakamura M, Kinoshita S. Keratinocyte growth factor accelerates corneal epithelial wound healing in vivo. Invest Ophthalmol Vis Sci. 1995;36:1524-1529.
32. Chandrasekher G, Kakazu AH, Bazan HE. HGF-and KGFinduced activation of PI-3K/p70 s6 kinase pathway in corneal epithelial cells: its relevance in wound healing. Exp Eye Res. 2001;73:191-202.
33. Pastor JC, Calonge M. Epidermal growth factor and corneal wound healing. A multicenter study. Cornea. 1992;11:311-314.
34. Iyer P, Maddala R, Pattabiraman PP, Rao PV. Connective tissue growth factor-mediated upregulation of neuromedin U expression in trabecular meshwork cells and its role in homeostasis of aqueous humor outflow. Invest Ophthalmol Vis Sci. 2012;53:4952-4962.
35. Battegay EJ, Raines EW, Seifert RA, Bowen-Pope DF, Ross R. Transforming growth factor beta induces bimodal proliferation of connective tissue cells via complex control of an autocrine platelet-derived growth factor loop. Cell. 1990;63: 515-524.
36. Roberts AB, Sporn MB, Assoian RK, et al. Transforming growth factor type B: rapid induction of fibrosis and angiogenesis in vivo and stimulation of collagen formation in-vitro. Proc Natl Acad Sci U S A. 1986;83:4167-4171.
37. Tomasek JJ, McRae J, Owens GK, Haaksma CJ. Regulation of alpha-smooth muscle actin expression in granulation tissue myofibroblasts is dependent on the intronic CArG element and the transforming growth factor-beta1 control element. Am J Pathol. 2005;166:1343-1351.
38. Imanishi J, Kamiyama K, Iguchi I, Kita M, Sotozono C, Kinoshita S. Growth factors: importance in wound healing and maintenance of transparency of the cornea. Pro Retin Eye Res. 2000;19:113-129.
39. Tamm ER, Fuchshofer R. What increases outflow resistance in primary open-angle glaucoma?Surv Ophthalmol. 2007;52: 101-104.
40. Tovar-Vidales T, Clark AF, Wordinger RJ. Transforming growth factor-beta2 utilizes the canonical Smad signaling pathway to regulate tissue transglutaminase expression in human trabecular meshwork cells. Exp Eye Res. 2011;93:442-451.
41. Cordeiro MF, Gay J, Khaw PT. Human anti-transforming growth factor-beta2 antibody: a new glaucoma anti-scarring agent. Invest Ophthalmol Vis Sci. 1999;40:2225-2234.
42. Khaw PT, Grehn F, Hollo G, et al. A phase III study of subconjunctival human anti-transforming growth factor beta(2) monoclonal antibody (CAT-152) to prevent scarring after first-time trabeculectomy. Ophthalmology. 2007;114: 1822-1830.
43. Mead AL, Wong TT, Cordeiro MF, Anderson IK, Khaw PT. Evaluation of anti-TGF-beta2 antibody as a new postoperative anti-scarring agent in glaucoma surgery. Invest Ophthalmol Vis Sci. 2003;44:3394-3401.
44. Spitzer M, Sat M, Schramm C, et al. Biocompatibility and antifibrotic effect of UV-cross-linked hyaluronate as a release system for tranilast after trabeculectomy in a rabbit model-a pilot study. Curr Eye Res. 2012;37:463-470.
45. Tsapara A, Luthert P, Greenwood J, Hill CS, Matter K, Balda MS. The RhoA activator GEF-H1/Lfc is a transforming growth factor-btarget gene and effector that regulates alpha-smooth muscle actin expression and cell migration. Mol Biol Cell. 2010;21:860-870.
46. Wick G, Backovic A, Rabensteiner E, Plank N, Schwentner C, Sgonc R. The immunology of fibrosis: innate and adaptive responses. Trends Immunol. 2010;31:110-119.
47. Wang N, Chintala SK, Fini ME, Schuman JS. Activation of a tissue specific stress response in the aqueous outflow pathway of the eye defines the glaucoma disease phenotype. Nat Med. 2001;7:304-309.
48. Liton PB, Li G, Luna C, Gonzalez P, Epstein DL. Cross-talk between TGF-beta1 and IL-6 in human trabecular meshwork cells. Mol Vis. 2009;15:326-334.
49. Vincenti MP, Brinckerhoff CE. Transcriptional regulation of collagenase (MMP-1, MMP-13) genes in arthritis: integration of complex signaling pathways for the recruitment of genespecific transcription factors. Arthritis Res. 2002;4:157-164.
50. Vincenti MP, Brinckerhoff CE. Signal transduction and celltype specific regulation of matrix metalloproteinase gene expression: can MMPS be good for you?J Cell Physiol. 2007; 213:355-364.
51. Garrington TP, Johnson GL. Organization and regulation of mitogen-activated protein kinase signaling pathways. Curr Opin Cell Biol. 1999;11:211-218.
52. Davis RJ. Signal transduction by the JNK group of MAP kinases. Cell. 2000;103:239-252.
53. Kolch W. Meaningful relationships: the regulation of the Ras/ Raf/MEK/ERK pathway by protein interactions. Biochem J. 2000;351:289-305.
54. Karin M. The regulation of AP-1 activity by mitogen-activated protein kinases. J Biol Chem. 1995;270:16483-16486.
55. Bates DO, Jones ROP. The role of vascular endothelial growth factor in wound healing. Int J Low Extrem Wounds. 2003;2: 107-120.
56. Li Z, Van Bergen T, Van de Veire S, et al. Inhibition of vascular endothelial growth factor reduces scar formation after glaucoma filtration surgery. Invest Ophthalmol Vis Sci. 2009;50:5217-5225.
57. Wilgus TA, Ferreira AM, Oberyszyn TM, Bergdall VK, DiPietro LA. Regulation of scar formation by vascular endothelial growth factor. Lab Invest. 2008;88:579-590.
58. Habot-Wilner Z, Barequet IS, Ivanir Y, Moisseiev J, Rosner M. The inhibitory effect of different concentrations of topical bevacizumab on corneal neovascularization. Acta Ophthalmol. 2010;88:862-867.
59. Manzano RP, Peyman GA, Khan P, et al. Inhibition of experimental corneal neovascularisation by bevacizumab (Avastin). Br J Ophthalmol. 2007;91:804-807.
60. Papathanassiou M, Theodossiadis PG, Liarakos VS, Rouvas A, Giamarellos-Bourboulis EJ, Vergados IA. Inhibition of corneal neovascularisation by subconjunctival bevacizumab in an animal model. Am J Ophthalmol. 2008;145:424-431.
61. Lee SH, Leem HS, Jeong SM, Lee K. Bevacizumab accelerates corneal wound healing by inhibiting TGF-b2 expression in alkali-burned mouse cornea. BMB Rep. 2009;42:800-805.
62. Cho YK, Zhang X, Uehara H, Young JR, Archer B, Ambati B. Vascular endothelial growth factor receptor 1 morpholino increases graft survival in a murine penetrating keratoplasty model. Invest Ophthalmol Vis Sci. 2012;53:8458-8471.
63. Memarzadeh F, Varma R, Lin L, et al. Postoperative use of bevacizumab as an antifibrotic agent in glaucoma filtration surgery in the rabbit. Invest Ophthalmol Vis Sci. 2009;50: 3233-3237.
64. How A, Chua JLL, Charlton A, et al. Combined treatment with bevacizumab and 5-fluorouracil attenuates the postoperative scarring response after experimental glaucoma filtration surgery. Invest Ophthalmol Vis Sci. 2010;51:928-932.
65. Rodríguez-Agirretxe I, Vega SC, Rezola R, et al. The PLGA implant as an antimitotic delivery system after experimental trabeculectomy. Invest Ophthalmol Vis Sci. 2013;54:5227-5235.
66. Nilforushan N, Yadgari M, Kish S, Nassiri N. Subconjunctival bevacizumab versus mitomycin C adjunctive to trabeculectomy. Am J Ophthalmol. 2012;153:352-357.
67. Chai J, Jones MK, Tarnawski AS. Serum response factor is a critical requirement for VEGF signaling in endothelial cells and VEGF-induced angiogenesis. FASEB J. 2004;18:1264-1266.
68. Awasthi N, Guo S, Wagner BJ. Posterior capsular opacification, a problem reduced but not yet eradicated. Arch Ophthalmol. 2009;127:555-562.
69. Jensen AA, Basti S, Greenwald MJ, Mets MB. When may the posterior capsule be preserved in pediatric intraocular lens surgery?Ophthalmology. 2002;109:324-327.
70. Cobo LM, Ohsawa E, Chandler D, Arguello R, George G. Pathogenesis of capsular opacification after extracapsular cataract extraction: an animal model. Ophthalmology. 1984; 91:857-863.
71. Wormstone IM. Posterior capsule opacification: a cell biological perspective. Exp Eye Res. 2002;74:337-347.
72. Wong TTL, Daniels JT, Crowston JG, Khaw PT. MMP inhibition prevents human lens epithelial cell migration and contraction of the lens capsule. Br J Ophthalmol. 2004;88: 868-872.
73. Nishi O, Nishi K, Fujiwara T, Shirasawa E, Ohmoto Y. Effects of the cytokines on the proliferation of and collagen synthesis by human cataract lens epithelial cells. Br J Ophthalmol. 1996;80:63-68.
74. Liu J, Hales AM, Chamberlain CG, McAvoy JW. Induction of cataract-like changes in rat lens epithelial explants by transforming growth factor b. Invest Ophthalmol Vis Sci. 1994;35:388-401.
75. Hales AM, Chamberlain CG, McAvoy JW. Cataract induction in lenses cultured with transforming growth factor-b. Invest Ophthalmol Vis Sci. 1995;36:1709-1713.
76. Gupta M, Korol A, West-Mays JA. Nuclear translocation of myocardin-related transcription factor-A during transforming growth factor beta-induced epithelial to mesenchymal transition of lens epithelial cells. Mol Vis. 2013;19:1017-1028.
77. Aslam TM, Devlin H, Dhillon B. Use of Nd:YAG laser capsulotomy. Surv Ophthalmology. 2003;48:594-612.
78. Haus CM, Galand AL. Mitomycin against posterior capsular opacification: an experimental study in rabbits. Br J Ophthalmol. 1996;80:1087-1091.
79. Ruiz JM, Medrano M, Alio JL. Inhibition of posterior capsule opacification by 5-fluorouracil in rabbits. Ophthalmic Res. 1990;22:201-208.
80. Power WJ, Neylan D, Collum LM. Daunomycin as an inhibitor of human lens epithelial cell proliferation in culture. J Cataract Refract Surg. 1994;20:287-290.
81. Cortina P, Gomez-Lechon MJ, Navea A, Menezo JL, Terencio MC, Diaz-Llopis M. Diclofenac sodium and cyclosporin A inhibit human lens epithelial cell proliferation in culture. Graefes Arch Clin Exp Ophthalmol. 1997;235:180-185.
82. Chandler HL, Barden CA, Lu P, Kusewitt DF, Colitz CM. Prevention of posterior capsular opacification through cyclooxygenase-2 inhibition. Mol Vis. 2007;13:677-691.
83. Behar-Cohen FF, David T, D'Hermies F, et al. In vivo inhibition of lens regrowth by fibroblast growth factor 2-saporin. Invest Ophthalmol Vis Sci. 1995;36:2434-2448.
84. Maloof A, Neilson G, Milverton EJ, Pandey SK. Selective and specific targeting of lens epithelial cells during cataract surgery using sealed-capsule irrigation. J Cataract Refract Surg. 2003;29:1566-1568.
85. Kim SY, Kim JH, Choi JS, Joo CK. Comparison of posterior capsule opacification in rabbits receiving either mitomycin-C or distilled water for sealed-capsule irrigation during cataract surgery. Clin Exp Ophthalmol. 2007;35:755-758.
86. Owen CG, Fletcher AE, Donoghue M, Rudnicka AR. How big is the burden of visual loss caused by age related macular degeneration in the United Kingdom? Br J Ophthalmol. 2003;87:312-317.
87. Hammes HP, Feng Y, Pfister F, Brownlee M. Diabetic retinopathy: targeting vasoregression. Diabetes. 2011;60:9-16.
88. Sapieha P, Joyal JS, Rivera JC, et al. Retinopathy of prematurity: understanding ischemic retinal vasculopathies at an extreme of life. J Clin Invest. 2010;120:3022-3032.
89. Garweg JG, Tappeiner C, Halberstadt M. Pathophysiology of proliferative vitreoretinopathy in retinal detachment. Surv Ophthalmol. 2013;58:321-329.
90. Friedlander M. Fibrosis and diseases of the eye. J Clin Invest. 2007;117:576-586.
91. Bharadwaj AS, Appukuttan B, Wilmarth PA, et al. Role of the retinal vascular endothelial cell in ocular disease. Prog Retin Eye Res. 2013;32:102-180.
92. Weinl C, Riehle H, Park D, et al. Endothelial SRF/MRTF ablation causes vascular disease phenotypes in murine retinae. J Clin Invest. 2013;123:2193-2206.
93. Ye X, Wang Y, Nathans J. The Norrin/Frizzled4 signaling pathway in retinal vascular development and disease. Trends Mol Med. 2010;16:417-425.
94. Yannuzzi LA, Negraõ S, Iida T, et al. Retinal angiomatous proliferation in age-related macular degeneration. Retina. 2001;21:416-434.
95. Chew E, Gillies M, Bird A. Macular telangiectasia: a simplified classification. Arch Ophthalmol. 2006;124:573-574.
96. Franco CA, Mericskay M, Parlakian A, et al. Serum response factor is required for sprouting angiogenesis and vascular integrity. Dev Cell. 2008;15:448-461.
97. Wei K, Che N, Chen F. Myocardin-related transcription factor B is required for normal mouse vascular development and smooth muscle gene expression. Dev Dyn. 2007;236:416-425.
98. Aiello LP. Vascular endothelial growth factor and the eye: biochemical mechanisms of action and implications for novel therapies. Ophthalmic Res. 1997;29:354-362.
99. Das A, McLamore A, Song W, McGuire PG. Retinal neovascularization is suppressed with a matrix metalloproteinase inhibitor. Arch Ophthalmol. 1999;117:498-503.
100. Ozerdem U, Mach-Hofacre B, Cheng L, et al. The effect of prinomastat (AG3340), a potent inhibitor of matrix metalloproteinases, on a subacute model of proliferative vitreoretinopathy. Curr Eye Res. 2000;20:447-453.
101. Lu Q, Longo FM, Zhou H, Massa SM, Chen YH. Signaling through Rho GTPase pathway as viable drug target. Curr Med Chem. 2009;16:1355-1365.
102. Gauvin TJ, Fukui J, Peterson JR, Higgs HN. Isoform-selective chemical inhibition of mDia-mediated actin assembly. Biochemistry. 2009;48:9327-9329.
103. Rizvi SA, Neidt EM, Cui J, et al. Identification and characterization of a small molecule inhibitor of forminmediated actin assembly. Chem Bio. 2009;16:1158-1168.
104. Evelyn CR, Wade SM, Wang Q, et al. CCG-1423: a smallmolecule inhibitor of RhoA transcriptional signaling. Mol Cancer Ther. 2007;6:2249-2260.
105. Inoue T, Tanihara H. Rho-associated kinase inhibitors: a novel glaucoma therapy. Prog Retin Eye Res. 2013;37:1-12.
106. Bell JL, Haak AJ, Wade SM, Kirchhoff PD, Neubig RR, Larsen SD. Optimization of novel nipecotic bis(amide) inhibitors of the Rho/MKL1/SRF transcriptional pathway as potential antimetastasis agents. Bioorg Med Chem Lett. 2013;23:3826-3832.
107. Sandbo N, Kregel S, Taurin S, Bhorade S, Dulin NO. Critical role of serum response factor in pulmonary myofibroblast differentiation induced by TGF-beta. Am J Respir Cell Mol Biol. 2009;41:332-338.
108. Sandbo N, Ngam C, Torr E, Kregel S, Kach J, Dulin N. Control of myofibroblast differentiation by microtubule dynamics through a regulated localization of mDia2. J Biol Chem. 2013; 288:15466-15473.
109. Lundquist MR, Storaska AJ, Liu TC, et al. Redox modification of nuclear actin by MICAL-2 regulates SRF signaling. Cell. 2014;156:563-576.
110. Hayashi K, Watanabe B, Nakagawa Y, Minami S, Morita T. RPEL proteins are the molecular targets for CCG-1423, an inhibitor of Rho signaling. PLoS One. 2014;9:e89016.
111. Parkinson G, Gaisford S, Ru Q, et al. Characterisation of ilomastat for prolonged ocular drug release. AAPS PharmSciTech. 2012;13:1063-1072.
112. Haller JA. Current anti-vascular endothelial growth factor dosing regimens: benefits and burden. Ophthalmology. 2013; 120(suppl 5):S3-S7.
113. Heatley G, Kiland J, Faha B, et al. Gene therapy using p21WAF-1/Cip-1 to modulate wound healing after glaucoma trabeculectomy surgery in a primate model of ocular hypertension. Gene Ther. 2004;11:949-955.
114. Perkins TW, Faha B, Ni M, et al. Adenovirus-mediated gene therapy using human p21WAF-1/Cip-1 to prevent wound healing in a rabbit model of glaucoma filtration surgery. Arch Ophthalmol. 2002;120:941-949.
115. Li N, Cui J, Duan X, Chen H, Fan F. Suppression of type I collagen expression by miR-29b via PI3K, Akt, and Sp1 pathway in human tenon's fibroblasts. Invest Ophthalmol Vis Sci. 2012;53:1670-1678.
116. Gallas A, Alexander C, Davies M, Purib S, Allen S. Chemistry and formulations for siRNA therapeutics. Chem Soc Rev. 2013;42:7983-7997.
117. Huang K, Dentchev T, Stambolian D. MiRNA expression in the eye. Mamm Genome. 2008;19:510-516.
118. Kaiser PK, Symons RC, Shah SM, et al. RNAi-based treatment for neovascular age-related macular degeneration by Sirna-027. Am J Ophthalmol. 2010;150:33-39.
119. Seet LF, Su R, Barathi VA, et al. SPARC deficiency results in improved surgical survival in a novel mouse model of glaucoma filtration surgery. PLoS One. 2010;5:e9415.
120. Velez G, Weingarden AR, Lei H, Kazlauskas A, Gao G. SU9518 inhibits proliferative vitreoretinopathy in fibroblast and genetically modified Müller cell-induced rabbit models. Invest Ophthalmol Vis Sci. 2013;54:1392-1397.
121. Kim B, Abdel-Rahman MH, Wang T, Pouly S, Mahmoud AM, Cebulla CM. Retinal MMP-12, MMP-13, TIMP-1, and TIMP-2 expression in murine experimental retinal detachment. Invest Ophthalmol Vis Sci. 2014;55:2031-2040.